Clinical trials: Neoplasm, Oral
Oral Squamous Cell Carcinoma
Toluidine Blue Versus Frozen Sections for Assessment of Tumor Margins in Oral Squamous Cell Carcinoma
The purpose of this study is to test the accuracy of toluidine blue in the assessment of intraoperative tumor margin after excision of oral squamous cell carcinoma(OSCC)in comparison to H\&E stain on frozen section.
- Trial name
- NCT03554967
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Cairo University
Oral Cancer
Behavior Change on Oral Cancer Patients After a Localized Behavior Change Model Intervention
The purpose of this research is to apply this smoking cessation program on oral cancer patients, and to analyze the effectiveness of it.
- Trial name
- NCT01351532
- Testing
- smoking cessation program, Lifestyle counseling
- Where
- Taiwan
- Volunteers
- 67 people
- Sponsor
- China Medical University Hospital
NSCLC, Ovarian Cancer
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations.
- Conditions
- NSCLC, Ovarian Cancer, Melanoma, Other Solid Tumors
- Trial name
- NCT02607813
- Testing
- LXH254, PDR001
- Where
- 18 sites in United States, Canada and 8 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of…
- Conditions
- Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer
- Trial name
- NCT05256290
- Testing
- silevertinib (BDTX-1535) monotherapy
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Radiation-induced Oral Mucositis, Head and Neck Cancer
Citrus Sinensis Peel Gel for Radiation-Induced Oral Mucositis
This randomized controlled clinical trial aims to evaluate the efficacy of Citrus sinensis peel extract gel in the treatment of radiation-induced oral mucositis in head and neck cancer patients.
- Trial name
- NCT07813923
- Testing
- Citrus sinensis peel extract gel, Conventional supportive treatment
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Alexandria University
Oral Lichen Planus
Topical Erythropoietin Hydrogel in Management of Oral Lichen Planus
The purpose of this study is to compare the clinical efficacy of erythropoietin gel containing a solution of 4000 units with triamcinolone acetonide 0.1% gel in the treatment of symptomatic oral lichen planus (OLP)
- Trial name
- NCT06135259
- Testing
- erythropoietin, Triamcinolone acetonide
- Volunteers
- 18 people
- Sponsor
- Ain Shams University
Oral Epithelial Dysplasia
Early Diagnosis of Oral Cancer by Detecting p16 Hydroxymethylation
The purpose of this study is to verify the function of p16 hydroxymethylation diagnostic reagents in early diagnosis of oral cancer.
- Trial name
- NCT02967120
- Testing
- no intervention
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Beijing Municipal Administration of Hospitals
Acute Myeloid Leukemia
Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients
Extension study, pilot, single-arm, compassionate use of Hikma Azacitidine 300 mg Film coated tablets test product for the Acute Myeloid Leukaemia (AML) patients who completed Hikma bioequivalence study with protocol number…
- Trial name
- NCT06572982
- Testing
- Azacitidine
- Where
- United Arab Emirates
- Volunteers
- 20 people
- Sponsor
- Hikma Pharmaceuticals LLC
Lymphoma
Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00003113
- Testing
- filgrastim, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Neoplasms
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a
Background: HIF-1 is a common mediator of hypoxic and non-hypoxic pathways that affects a transcriptional program leading to survival, angiogenesis, migration and invasion of cancer cells.
- Trial name
- NCT00117013
- Testing
- Fluorine-19-Fluoroded Xyglucose, Topotecan
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Myeloid Leukemia, Philadelphia Positive
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
The aim of this study is to support development of asciminib in the pediatric population (1 to <18 years) previously treated with one or more TKIs.
- Trial name
- NCT04925479
- Testing
- Asciminib Pediatric formulation group, Asciminib Adult formulation group
- Where
- 39 sites in United States, China and 12 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Oral Mucositis
The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients
The purpose of this study is to explore the protective effect and safety of soluble beta-1,3/1,6-glucan compared to placebo in oral mucositis in head and neck patients receiving radiotherapy or chemoradiotherapy.
- Trial name
- NCT00289003
- Testing
- Soluble beta-1,3/1,6-glucan
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Biotec Pharmacon ASA
Solid Tumors, Triple-Negative Breast Cancer
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.
- Conditions
- Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT02071862
- Testing
- CB-839, Pac-CB, CBE
- Where
- 13 sites in United States
- Volunteers
- 210 people
- Sponsor
- Calithera Biosciences, Inc
Unspecified Adult Solid Tumor, Protocol Specific
Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Lenalidomide may stop the growth of solid tumors by blocking blood flow to the tumor. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00415116
- Testing
- carboplatin, docetaxel, lenalidomide
- Volunteers
- 14 people
- Sponsor
- The Cleveland Clinic
Nasopharyngeal Carcinoma
Comparison of Oxycodone to Control Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy
Background:Although concurrent chemoradiotherapy is effective for improving disease-free survival and overall survival in patients with locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT03045484
- Testing
- Controlled-release oxycodone, Chemoradiotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumor
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors
This is a first-in-human (FIH), multicenter, open-label, phase I study to evaluate the safety, tolerability, PK and preliminary efficacy of GenSci122 in participants with advanced solid tumors.
- Trial name
- NCT06772415
- Testing
- GenSci122 tablet 50mg, GenSci122 tablet 250mg
- Where
- 9 sites in China
- Volunteers
- 163 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Non Squamous Non Small Cell Lung
SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer
The present trial will be performed to evaluate whether SHR1020 in combination with docetaxel in patients with Local Advanced or Metastatic or recurrent Non Squamous NSCLC is more effective as compared to placebo in combination…
- Trial name
- NCT02766140
- Testing
- SHR1020 plus Docetaxel
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Cancer, Non-Small Cell Lung Cancer
Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer
To determine the toxicities, maximum tolerated dose (MTD) and recommended phase 2 dose of MKC-1 when administered orally, twice daily for 14 days followed by 7 days without dosing, in combination with pemetrexed (delivered at its…
- Trial name
- NCT00408226
- Testing
- MKC-1, pemetrexed
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- CASI pharmaceuticals, Inc.
Cancer, Solid Tumors
Study of XL418 in Adults With Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of XL418 in subjects with solid tumors. XL418 is a new chemical entity that inhibits a spectrum of targets, including Akt and p70S6K, that mediate PI3 Kinase /…
- Trial name
- NCT00460278
- Testing
- XL418
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- Exelixis
Oral Anti-Tumor Drugs, Oral Antineoplastic Agents
Educational Intervention on Oral Anticancer Agents for Community Pharmacists
The overall aim of this study is to develop and test the feasibility and acceptability of an educational intervention for community pharmacists to provide support to patients receiving oral anticancer agents (OAAs) in the…
- Conditions
- Oral Anti-Tumor Drugs, Oral Antineoplastic Agents, Oral Anticancer Drugs
- Trial name
- NCT07677176
- Testing
- Educational intervention on managing oral anticancer agents in community pharmacy setting
- Where
- Malaysia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Monash University Malaysia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.